For US Healthcare Professionals

I am a

Options for Administration

INDUCTION DOSING1

TREMFYA® starter pack
TREMFYA® starter pack
Not actual size.

INDUCTION—SC

3 SC TREMFYA® PEN
Induction Packs*

400 mg SC injection (given as two consecutive injections of 200 mg each) at Weeks 0, 4, and 8

Induction dosing schedule: Week 0, Week 4, & Week 8

TREMFYA® is also available in 200 mg prefilled syringes

OR

TREMFYA® is also available in 200 mg prefilled syringes

OR

IV infusion
IV infusion
Not actual size.

INDUCTION—IV

IV infusion (200 mg)–
3 IV induction doses†

200 mg IV infusion administered over at least 1 hour at Weeks 0, 4, and 8

Induction dosing schedule: Week 0, Week 4, & Week 8

*Induction Pack for ulcerative colitis: Carton containing two 200 mg/2 mL single-dose prefilled pens (400 mg/4 mL total) (TREMFYA® PEN).1

†200 mg/20 mL (10 mg/mL) solution in a single-dose vial.1

MAINTENANCE DOSING

TREMFYA® PEN (200 mg)
Not actual size.

TREMFYA® PEN (200 mg)1‡

200 mg administered by SC injection at Week 12, and every 4 weeks thereafter

Maintenance dosing for TREMFYA® PEN (200 mg): administered by SC injection at Week 12 and every 4 weeks thereafter

Also available in prefilled syringe (200 mg/2 mL)

Maintenance dosing for TREMFYA® PEN (200 mg): administered by SC injection at Week 12 and every 4 weeks thereafter

Also available in prefilled syringe (200 mg/2 mL)

OR

TREMFYA® PEN (100 mg)
Not actual size.

TREMFYA® PEN (100 mg)1§

100 mg administered by SC injection at Week 16, and every 8 weeks thereafter

Maintenance dosing for TREMFYA® PEN (100 mg): administered by SC injection at Week 16 and every 8 weeks thereafter

Also available in One-Press patient-controlled
injector or prefilled syringe (100 mg/mL)

Maintenance dosing for TREMFYA® PEN (100 mg): administered by SC injection at Week 16 and every 8 weeks thereafter

Also available in One-Press patient-controlled injector or prefilled syringe (100 mg/mL)

Use the lowest effective recommended dosage to maintain therapeutic response.

‡200 mg/2 mL in a single-dose prefilled pen.1

§100 mg/mL in a single-dose prefilled pen.1

Pretreatment Evaluations: Evaluate for tuberculosis (TB) infection, obtain liver enzymes and bilirubin levels, and complete all age-appropriate vaccinations according to current immunization guidelines.1

Monitor: For signs and symptoms of active TB during and after treatment with TREMFYA®; liver enzymes and bilirubin levels for at least 16 weeks of treatment, and periodically thereafter according to routine patient management.1

TREMFYA® is intended for use under the guidance and supervision of a healthcare professional. TREMFYA® may be administered by a healthcare professional, or a patient/caregiver after proper training on correct subcutaneous injection technique.1

IL-23i=interleukin-23 inhibitor; IV=intravenous; SC=subcutaneous.

HOW TO PRESCRIBE

Write 2 prescriptions for TREMFYA®1

Write 1 prescription for induction dosing and 1 prescription for maintenance dosing 

RX #1 SC or IV induction dosing

Rx for TREMFYA® PEN Induction Pack

OR

Rx for TREMFYA® 200 mg IV

RX #2 SC MaintEnance dosing

Rx for TREMFYA® 200 mg SUBQ

OR

Rx for TREMFYA® 100 mg SUBQ

Write one Rx for TREMFYA® for induction dosing and one Rx for maintenance dosing

Recommended Dosing for Ulcerative Colitis:

  • Induction Dose: 400 mg administered by SC injection (given as two consecutive injections of 200 mg each) at Weeks 0, 4, and 8 or 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8
  • Maintenance Dose: 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic response

Please refer to the full Prescribing Information for the complete dosing information.

Pretreatment Evaluations: Evaluate for tuberculosis (TB) infection, obtain liver enzymes and bilirubin levels, and complete all age-appropriate vaccinations according to current immunization guidelines.1

Monitor: For signs and symptoms of active TB during and after treatment with TREMFYA®; liver enzymes and bilirubin levels for at least 16 weeks of treatment, and periodically thereafter according to routine patient management.1

TREMFYA® is intended for use under the guidance and supervision of a healthcare professional. TREMFYA® may be administered by a healthcare professional, or a patient/caregiver after proper training on correct subcutaneous injection technique.1

IV=intravenous; q4w=every 4 weeks; q8w=every 8 weeks; SC=subcutaneous; SUBQ=subcutaneous. 

DEVICES

For your patients’ maintenance doses, TREMFYA® is available as 3 different devices1

200 mg/2 mL1

TREMFYA® PEN

TREMFYA® PEN 200-mg dose image
TREMFYA® PEN 200-mg dose image

Not actual size.

TREMFYA® PEN

TREMFYA® comes in a single-dose prefilled pen containing one 200 mg dose. Each TREMFYA® PEN can be used only one time.

OR

Prefilled syringe

TREMFYA® prefilled syringe 200-mg dose

Not actual size.

Prefilled syringe

TREMFYA® comes as a single-dose prefilled syringe containing one 200 mg dose. Each TREMFYA® prefilled syringe can be used only one time.

Also in

100 mg/mL1

TREMFYA® PEN

TREMFYA® PEN 100-mg dose

Not actual size.

TREMFYA® PEN

TREMFYA® comes in a single-dose prefilled pen containing one 100 mg dose. Each TREMFYA® PEN can be used only one time.

OR

Prefilled syringe

TREMFYA® prefilled syringe 100-mg dose
TREMFYA® prefilled syringe 100-mg dose

Not actual size.

Prefilled syringe

TREMFYA® comes as a single-dose prefilled syringe containing one 100 mg dose. Each TREMFYA® prefilled syringe can be used only one time.

OR

One-Press

TREMFYA® One-Press injector 100-mg dose

Not actual size.

One-Press

TREMFYA® comes in a single-dose One-Press patient-controlled injector containing one 100 mg dose. Each One-Press injector can be used only one time.

Once you have determined the appropriate dose for your patient, you and your patient can choose which device may be best suited for them.1

Please see the full Instructions for Use for the TREMFYA® PEN, One-Press patient-controlled injector, and prefilled syringe.

Demonstration Videos

These videos are not meant to replace the Instructions for Use (IFU) that are supplied with TREMFYA®. Instruct patients to read the IFU before using their TREMFYA® PEN, TREMFYA® prefilled syringe, or One-Press patient-controlled injector and each time they get a refill. Please see the full IFU for TREMFYA®.

TREMFYA® PEN Demonstration

TREMFYA® PEN demonstration video thumbnail
TREMFYA® PEN demonstration video thumbnail

TREMFYA® Syringe Demonstration

TREMFYA® syringe demonstration video thumbnail
TREMFYA® syringe demonstration video thumbnail

TREMFYA® One-Press Demonstration

TREMFYA® One-Press demonstration video thumbnail
TREMFYA® One-Press demonstration video thumbnail

TREMFYA® is intended for use under the guidance and supervision of a healthcare professional. TREMFYA® may be administered by a healthcare professional, or a patient/caregiver after proper training on correct subcutaneous injection technique.

teal vector
teal vector

Schedule a meeting with a local representative of Johnson & Johnson

Request a rep

Explore TREMFYA® Efficacy

Banner Image

References: 1. TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie Inc. 3. Omvoh® [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.